Ocugen Inc
NASDAQ:OCGN

Watchlist Manager
Ocugen Inc Logo
Ocugen Inc
NASDAQ:OCGN
Watchlist
Price: 1.02 USD -4.67% Market Closed
Market Cap: 293.6m USD
Have any thoughts about
Ocugen Inc?
Write Note

Intrinsic Value

OCGN's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one OCGN stock under the Base Case scenario is 0.3 USD. Compared to the current market price of 1.02 USD, Ocugen Inc is Overvalued by 71%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

OCGN Intrinsic Value
0.3 USD
Overvaluation 71%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Ocugen Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for OCGN cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about OCGN?
Bearish
Neutral
Bullish

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Ocugen Inc

Provide an overview of the primary business activities
of Ocugen Inc.

What unique competitive advantages
does Ocugen Inc hold over its rivals?

What risks and challenges
does Ocugen Inc face in the near future?

Summarize the latest earnings call
of Ocugen Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Ocugen Inc.

Provide P/S
for Ocugen Inc.

Provide P/E
for Ocugen Inc.

Provide P/OCF
for Ocugen Inc.

Provide P/FCFE
for Ocugen Inc.

Provide P/B
for Ocugen Inc.

Provide EV/S
for Ocugen Inc.

Provide EV/GP
for Ocugen Inc.

Provide EV/EBITDA
for Ocugen Inc.

Provide EV/EBIT
for Ocugen Inc.

Provide EV/OCF
for Ocugen Inc.

Provide EV/FCFF
for Ocugen Inc.

Provide EV/IC
for Ocugen Inc.

Show me price targets
for Ocugen Inc made by professional analysts.

What are the Revenue projections
for Ocugen Inc?

How accurate were the past Revenue estimates
for Ocugen Inc?

What are the Net Income projections
for Ocugen Inc?

How accurate were the past Net Income estimates
for Ocugen Inc?

What are the EPS projections
for Ocugen Inc?

How accurate were the past EPS estimates
for Ocugen Inc?

What are the EBIT projections
for Ocugen Inc?

How accurate were the past EBIT estimates
for Ocugen Inc?

Compare the revenue forecasts
for Ocugen Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Ocugen Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Ocugen Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Ocugen Inc compared to its peers.

Compare the P/E ratios
of Ocugen Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Ocugen Inc with its peers.

Analyze the financial leverage
of Ocugen Inc compared to its main competitors.

Show all profitability ratios
for Ocugen Inc.

Provide ROE
for Ocugen Inc.

Provide ROA
for Ocugen Inc.

Provide ROIC
for Ocugen Inc.

Provide ROCE
for Ocugen Inc.

Provide Gross Margin
for Ocugen Inc.

Provide Operating Margin
for Ocugen Inc.

Provide Net Margin
for Ocugen Inc.

Provide FCF Margin
for Ocugen Inc.

Show all solvency ratios
for Ocugen Inc.

Provide D/E Ratio
for Ocugen Inc.

Provide D/A Ratio
for Ocugen Inc.

Provide Interest Coverage Ratio
for Ocugen Inc.

Provide Altman Z-Score Ratio
for Ocugen Inc.

Provide Quick Ratio
for Ocugen Inc.

Provide Current Ratio
for Ocugen Inc.

Provide Cash Ratio
for Ocugen Inc.

What is the historical Revenue growth
over the last 5 years for Ocugen Inc?

What is the historical Net Income growth
over the last 5 years for Ocugen Inc?

What is the current Free Cash Flow
of Ocugen Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Ocugen Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Ocugen Inc

Current Assets 18.6m
Cash & Short-Term Investments 15.7m
Other Current Assets 2.9m
Non-Current Assets 21.9m
PP&E 17.5m
Other Non-Current Assets 4.5m
Current Liabilities 18m
Accounts Payable 3.4m
Accrued Liabilities 4.5m
Other Current Liabilities 10.1m
Non-Current Liabilities 5.6m
Long-Term Debt 1.6m
Other Non-Current Liabilities 4.1m
Efficiency

Earnings Waterfall
Ocugen Inc

Revenue
8.2m USD
Operating Expenses
-59.9m USD
Operating Income
-51.7m USD
Other Expenses
5.8m USD
Net Income
-45.9m USD

Free Cash Flow Analysis
Ocugen Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

OCGN Profitability Score
Profitability Due Diligence

Ocugen Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.

21/100
Profitability
Score

Ocugen Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.

OCGN Solvency Score
Solvency Due Diligence

Ocugen Inc's solvency score is 55/100. The higher the solvency score, the more solvent the company is.

Negative Net Debt
Low D/E
Long-Term Solvency
Short-Term Solvency
55/100
Solvency
Score

Ocugen Inc's solvency score is 55/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

OCGN Price Targets Summary
Ocugen Inc

Wall Street analysts forecast OCGN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for OCGN is 6.38 USD with a low forecast of 4.04 USD and a high forecast of 8.4 USD.

Lowest
Price Target
4.04 USD
296% Upside
Average
Price Target
6.38 USD
525% Upside
Highest
Price Target
8.4 USD
724% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for OCGN?

Click here to dive deeper.

Dividends

Ocugen Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for OCGN is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

OCGN News

Other Videos

Profile

Ocugen Inc Logo
Ocugen Inc

Country

United States of America

Industry

Biotechnology

Market Cap

293.6m USD

Dividend Yield

0%

Description

Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. The company is headquartered in Malvern, Pennsylvania and currently employs 56 full-time employees. The company went IPO on 2014-12-03. The firm's technology pipeline includes: COVID-19 Vaccine (0.5), Modifier Gene Therapy Platform and Novel Biologic Therapies for Retinal Diseases. COVID-19 Vaccine candidate is focused on developing, manufacturing and commercializing COVAXIN for the prevention of COVID-19 in humans in the Ocugen Covaxin Territory. COVAXIN is a whole-virion inactivated COVID-19 vaccine candidate and is formulated with the inactivated SARS-CoV-2 virus. The Modifier Gene Therapy platform is designed for retinal diseases, including retinitis pigmentosa (RP), leber congenital amaurosis (LCA) and dry age-related macular degeneration (AMD). The company is developing OCU200, a biologic product candidate to treat diabetic macular edema (DME), diabetic retinopathy (DR) and wet AMD. OCU400, its first product candidate being developed with its modifier gene therapy platform.

Contact

PENNSYLVANIA
Malvern
263 Great Valley Parkway
+14843284701.0
ocugen.com

IPO

2014-12-03

Employees

56

Officers

Co-Founder, CEO & Chairman
Dr. Shankar Musunuri M.B.A., Ph.D.
Co-founder & Independent Director
Dr. Uday B. Kompella Ph.D.
Chief Scientific Officer and Head of Research & Development
Dr. Arun Upadhyay Ph.D.
General Counsel
John Kouch J.D.
AVP & Head of Corporate Communications
Ms. Tiffany J. Hamilton M.B.A.
Head of People & Culture
Ms. Kristen Craft
Show More
Senior Vice President of Commercial
Mr. Michael Shine M.B.A.
VP & Head of Regulatory & Quality
Ms. Jyothy Pillai M.S.
Chief Medical Officer
Dr. Huma Qamar CMI, M.D., M.P.H.
VP, Head of Program Management & Chief of Staff
Dr. Durgaprasad Annavajjula Ph.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one OCGN stock?

The intrinsic value of one OCGN stock under the Base Case scenario is 0.3 USD.

Is OCGN stock undervalued or overvalued?

Compared to the current market price of 1.02 USD, Ocugen Inc is Overvalued by 71%.

Back to Top